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Table 1. Associations with Leprosy for Replicated Single-Nucleotide Polymorphisms on Chromosome 13q14.11, According to Case–Control 
Population.*
SNP Gene Original Study Present Study New Delhi Kolkata Mali
Combined 
 Populations
odds ratio (95% CI) P value
rs3764147 C13orf31 1.68 (1.57–1.80) 1.59 (1.34–1.89) 2.7×10−3 6.4×10−2 1.1×10−5 6.1×10−8
rs9533634 CCDC122 0.76 (0.70–0.82) 0.70 (0.59–0.82) 1.5×10−3 3.6×10−1 1.1×10−5 1.1×10−5
* C13orf31 denotes the gene encoding chromosome 13 open reading frame 31, CCDC122 the gene encoding coiled-coil domain containing 
122, CI confidence interval, and SNP single-nucleotide polymorphism.
Genomewide Association Study of Leprosy
To the Editor: Zhang and colleagues (Dec. 31 
issue)1 report that genes in the nucleotide­bind­
ing oligomerization domain containing 2 (NOD2)–
mediated signaling pathway are associated with 
susceptibility to infection with Mycobacterium lep-
rae in China. India has the world’s greatest lep­
rosy disease burden. We therefore genotyped the 
single­nucleotide polymorphisms (SNPs) that were 
implicated by Zhang and colleagues in two Indian 
case–control cohorts (492 patients in New Delhi 
and 382 in Kolkata).2,3 We also genotyped 273 
cases and 221 controls from Mali, West Africa.4 
We observed associations between disease and 
SNPs at C13orf31 (the gene encoding chromosome 
13 open reading frame 31) (rs3764147, P = 6.1×10−8) 
and CCDC122 (the gene encoding coiled­coil do­
main containing 122) (rs9533634, P = 1.1×10−5) 
(Table 1); both genes were of unknown function. 
We did not, however, observe associations be­
tween disease and the other four non–major his­
tocompatibility complex (MHC) genes related to 
the NOD2 pathway (NOD2, RIPK2 [the gene encod­
ing receptor­interacting serine–threonine kinase 
2], TNFSF15 [the gene encoding tumor necrosis 
factor (ligand) superfamily member 15], and 
LRRK2 [the gene encoding leucine­rich repeat ki­
nase 2]) (Table 1 in the Supplementary Appendix, 
available with the full text of this letter at NEJM.
org), despite reasonable power to detect the ef­
fect sizes observed by Zhang et al.1 An analysis of 
27 additional SNPs at NOD2 in the New Delhi 
cohort provided support for the absence of a con­
sistent association at this locus (Table 2 in the 
Supplementary Appendix). These results indicate 
heterogeneity among populations and suggest 
that future functional studies should focus on 
populations in which the relevant genetic asso­
ciation may occur. Nevertheless, a robust asso­
ciation of the Crohn’s disease chromosome 
13q14.11 locus5 containing C13orf31 and CCDC122 
with leprosy in China, India, and Mali provides 
support for a molecular link between mycobacte­
rial infection and Crohn’s disease.
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To the Editor: In a genomewide association 
study, Zhang and colleagues identified the NOD2 
pathway associated with susceptibility to leprosy. 
Their findings were consistent with those of 
studies showing the role of NOD2 in the recogni­
tion of mycobacteria.1 However, NOD2 interacts 
with toll­like receptors (TLRs) during recognition 
of mycobacteria, and polymorphisms in either 
TLR22 or TLR43 have been shown to influence 
susceptibility to leprosy. Therefore, it may seem 
surprising that no signal of association was de­
tected between TLRs and leprosy in the study by 
Zhang et al.  An explanation of this apparent dis­
crepancy is that haplotypes in TLR genes vary 
greatly among populations in different geographic 
locations.4 For example, TLR4 polymorphisms 
that influence the susceptibility to infections are 
virtually absent in East Asia, in contrast to other 
populations.4 We therefore suggest that genome­
wide association studies involving African or Eu­
ropean populations would identify a different and 
possibly larger number of genes influencing sus­
ceptibility to leprosy.
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To the Editor: A similar proinflammatory im­
mune response has been observed in paucibacil­
lary leprosy and in the contained form of Crohn’s 
disease.1 In contrast, such an immune response 
has not been detected in the more aggressive, 
multibacillary form of leprosy and in the more 
aggressive form of Crohn’s disease.1 These find­
ings are now mirrored in an intriguing common­
ality between human genetic defects in multi­
bacillary leprosy and Crohn’s disease reported 
on by Zhang et al. The accompanying editorial2 
posits that a subgroup “of Crohn’s disease cases 
may have a mycobacterial cause.” A candidate 
culpable organism3 causes Johne’s disease in ru­
minants, an affliction evocative of Crohn’s dis­
ease. Interspecies comparisons4 may be illuminat­
ing. Cattle with the NOD2 defect are three times 
as likely to contract Johne’s disease as cattle with 
wild­type NOD2 in the same herd.5
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The Authors Reply: Using three case–control 
samples from India and West Africa, Wong et al. 
undertook a follow­up study of our recently iden­
tified leprosy susceptibility SNPs and confirmed 
the strong associations of C13orf31 and CCDC122, 
highlighting the commonality of leprosy suscep­
tibility loci among diverse populations. Although 
they did not detect the associations in the other 
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non­MHC susceptibility loci, the use of combined 
small and mixed patient cohorts, with limited 
analysis of the SNPs most strongly implicated in 
our analysis, may have resulted in some missed 
associations, especially if the risk alleles were 
tagged by different SNPs in populations of differ­
ing ancestries, the genetic effects of risk alleles 
were more moderate in populations other than 
Chinese populations, or both.
Netea and colleagues express surprise that our 
study did not highlight TLR genes and further 
imply that our findings may be relevant only for 
East Asian populations. We searched our genome­
wide association study data for any evidence of 
TLR associations and found none. We agree with 
these correspondents that genetic variation due 
to differences in ancestral origin may explain this 
result,1 but we think a more likely explanation is 
that the NOD2 pathway is more influential than 
the TLR pathway in determining disease outcome. 
The implication of variants of C13orf31 and 
CCDC122 in Indian and West African populations 
shows that genetic risk factors for leprosy are 
shared by different populations.
The observation by Greenstein and Brown pro­
vides further support for the pathogenicity com­
mon to leprosy and Crohn’s disease. Although 
we observed an overlap of the most strongly 
implicated SNPs in susceptibility to both leprosy 
and Crohn’s disease, a joint analysis of these dis­
eases (through a genomewide association study) 
should be pursued for a comprehensive investiga­
tion of common genetic risk factors. Moreover, 
confirmation of the association between C13orf31 
and CCDC122 and susceptibility to Crohn’s disease 
and leprosy in diverse populations calls for an 
investigation of the biologic function of these 
genes, which will probably illuminate a patho­
genic mechanism of both diseases.
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Barrett’s Esophagus
To the Editor: Sharma (Dec. 24 issue)1 says that 
ablation is not recommended for nondysplastic 
Barrett’s esophagus because of an unacceptably 
high number of patients who would need to be 
treated (the number needed to treat) to prevent 
one case of adenocarcinoma. The estimate of 250 
as the number needed to treat is artificially high, 
however. The number needed to treat is 1 divided 
by the absolute risk reduction. In the meta­analy­
sis by Wani et al., the incidence of adenocarcino­
ma in patients with untreated nondysplastic Bar­
rett’s esophagus was 0.6% per patient­year of 
follow­up, as compared with 0.16% in patients 
treated with ablation.2 The absolute risk reduction 
is therefore 0.6% − 0.16%, or 0.44% per patient­
year of follow­up. The studies in this meta­analy­
sis varied in the length of follow­up, but all fol­
low­ups were multiple years in length. Assuming 
a follow­up of just 5 years, the number needed to 
treat would be 45, not 250. Other studies of abla­
tion for nondysplastic Barrett’s esophagus also 
show a much lower number needed to treat — 
approximately 23 rather than 250.3
Sharma’s estimate of the number needed to 
treat limits ablation to prevention of adenocarci­
noma only; however, ablation also prevents the 
development of high­grade dysplasia and subse­
quent progression to cancer.4 For the inclusion of 
the aggregate end points of high­grade dysplasia 
and cancer, the number needed to treat would be 
lower still.
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